Anne Li May 6th, 2017
In 2015, Cancer Research UK wrote about some fascinating research from one of their scientists based at their Cambridge Institute, Dr Jason Carroll. Carroll and his team uncovered a possible explanation for why women whose breast cancer cells carry two key molecules – called the oestrogen and progesterone receptors – do better than those whose cells only carry the oestrogen receptor. Even when they receive the same treatment. They revealed that when signals were sent through the progesterone receptor it slowed down the growth of breast cancer cells. To find out if this had potential as a treatment, the researchers tested a new combination of hormone therapies and found it slowed down tumour growth in mice.
See original article at: https://scienceblog.cancerresearchuk.org/2017/05/05/taking-a-potential-new-breast-cancer-treatment-from-the-lab-to-the-clinic/
Post a comment